Sanofi: How I Leveraged This Undervalued Dividend Aristocrat

Sanofi is rated a Buy, with ~33.5% upside to €99.5 fair value (or $57 for SNY ADRs), resulting from averaging optimistic with pessimistic scenarios.

Dupixent remains Sanofi's key growth driver, with a €25B 2030 sales target, but faces biosimilar risk post-2031 and a significant lawsuit threat.

New pharma launches and pipeline assets are expected to offset legacy declines, targeting €10B in 2030 sales and with possible margin expansion toward 40%.

I implement a bull call spread strategy, targeting ~100% return with the stock 28%-29% higher, but limit position size due to Dupixent litigation.

Sanofi ( SNY ) has been punished by the market due to multiple pipeline failures recently.

That’s very important, indeed, because these pipeline candidates should have been a replacement for their blockbuster drug